
TCRT
Healthcare · Biotechnology · $6.9M market cap
$1.63+0.01 (+0.6%)Nov 13, 4:00 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2026 | Time not confirmed | — | — | — |
| Aug 14, 2026 | Time not confirmed | — | -0.41 | — |
| Nov 14, 2025 | Time not confirmed | — | -0.55 | — |
| Aug 14, 2025 | After the close | — | -0.63 | — |
| May 15, 2025 | Time not confirmed | — | -0.67 | — |
| Mar 31, 2025 | Before the open | — | -0.46 | — |
| Nov 12, 2024 | Before the open | — | -0.70 | — |
| Aug 14, 2024 | After the close | — | -0.71 | — |
| Apr 1, 2024 | Before the open | -4.50 | -17.09 | -279.8% |
| Mar 5, 2024 | Before the open | -0.45 | -0.49 | -8.9% |
| Nov 14, 2023 | Before the open | -5.25 | -4.41 | +16.0% |
| Aug 14, 2023 | After the close | -6.75 | -6.00 | +11.1% |
| May 10, 2023 | Before the open | -6.60 | -6.00 | +9.1% |
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc.…
| Mar 7, 2023 |
| Before the open |
| -0.07 |
| -0.04 |
| +42.9% |
| Nov 14, 2022 | Before the open | -10.75 | -6.00 | +44.2% |
| Aug 15, 2022 | Before the open | -10.25 | -7.50 | +26.8% |
| May 16, 2022 | Before the open | -9.90 | -7.50 | +24.2% |
| Mar 30, 2022 | Before the open | -0.08 | -0.05 | +37.5% |
| Nov 8, 2021 | After the close | -18.86 | -16.50 | +12.5% |
| Aug 13, 2021 | After the close | -17.57 | -16.50 | +6.1% |
| May 6, 2021 | After the close | -15.81 | -15.00 | +5.1% |
| Feb 25, 2021 | After the close | -0.10 | -0.11 | -10.0% |
| Nov 5, 2020 | After the close | -13.49 | -15.00 | -11.2% |
| Aug 6, 2020 | After the close | -13.75 | -13.50 | +1.8% |
| May 7, 2020 | After the close | -12.75 | -13.50 | -5.9% |
| Mar 2, 2020 | After the close | -0.08 | -0.09 | -12.5% |
| Nov 7, 2019 | After the close | -13.50 | -64.50 | -377.8% |
| Aug 8, 2019 | Before the open | -12.24 | -13.50 | -10.3% |
| May 8, 2019 | After the close | -12.30 | -12.00 | +2.4% |
| Mar 5, 2019 | After the close | -0.11 | -0.08 | +27.3% |
| Nov 9, 2018 | Before the open | -16.73 | -19.50 | -16.6% |
| Aug 8, 2018 | After the close | -18.52 | -18.00 | +2.8% |
| May 10, 2018 | After the close | -19.06 | -22.50 | -18.0% |
| Mar 1, 2018 | After the close | -0.14 | -0.13 | +7.1% |